[Evaluation of the treatment of cystic lymphangioma by percutaneous injection of Ethibloc in 20 patients].

Abstract

BACKGROUND:

Surgical treatment of cystic lymphangioma (CL) is so often followed by local and general complications that non invasive treatment must be considered.

POPULATION AND METHODS:

Between 1987 and 1993, 20 patients with a superficial macrocystic lymphangioma were treated by percutaneous injection of Ethibloc in order to reduce the volume of the CL, with a minimum follow-up of 1 year. Fourteen CL were cervico-facial and six were located in the upper half of the body. The size of the lesion was determined by echography: three CL were less than 5 cm in diameter, 12 between 5 and 10 cm, five more than 10 cm. Two to 5 mL of Ethibloc were injected during one (15 cases) or several sessions (five cases).

RESULTS:

Reduction in volume was excellent in 12 patients after one session and in four patients after several sessions. Four patients had a poor result. All the patients suffered from an important inflammatory reaction for 2 or 3 days followed by exteriorisation of the Ethibloc in seven patients, with a discrete final scar.

CONCLUSION:

These fair results suggest that intracystic injection of Ethibloc represents an effective alternative to surgery.

• Authors: V Martinot, S Descamps, P Février, P Patenotre, J M Brevière, F Piette, P Pellerin
• Journal: Archives de pediatrie : organe officiel de la Societe francaise de pediatrie (Arch Pediatr) Vol. 4 Issue 1 Pg. 8-14 (Jan 1997) ISSN: 0929-693X [Print] France
• Vernacular Title: Evaluation du traitement des lymphangiomes kystiques par injection percutanée d'Ethibloc chez 20 patients.
• PMID: 9084702 (Publication Type: English Abstract, Journal Article)

Chemical References

• Drug Combinations
• Fatty Acids
• Propylene Glycols
• Sclerosing Solutions
• Diatrizoate
• Zein
• alcoholic prolamine solution

Topics

• Adolescent
• Adult
• Brain Neoplasms (drug therapy)
• Child
• Child, Preschool
• Diatrizoate (administration & dosage, adverse effects, therapeutic use)
• Drug Combinations
• Facial Neoplasms (drug therapy)
• Fatty Acids (administration & dosage, adverse effects, therapeutic use)
• Female
• Humans
• Inflammation (chemically induced)
• Injections, Subcutaneous
• Lymphangioma, Cystic (drug therapy, pathology)
• Male
• Neck (pathology)
• Propylene Glycols (administration & dosage, adverse effects, therapeutic use)
• Prospective Studies
• Sclerosing Solutions (administration & dosage, adverse effects, therapeutic use)
• Zein (administration & dosage, adverse effects, therapeutic use)